CLDX NASDAQ
Celldex Therapeutics, Inc.
1W: -5.8%
1M: -10.6%
3M: +32.8%
YTD: +13.2%
1Y: +49.2%
3Y: -8.0%
5Y: +12.9%
$30.73
+0.15 (+0.49%)
Weekly Expected Move ±4.9%
$28
$30
$31
$33
$34
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (39)
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex Reports First Quarter Financial Results and Provides Corporate Update
Innoviva (INVA) Tops Q1 Earnings Estimates
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?
Celldex Therapeutics (NASDAQ:CLDX) Shares Pass Above 200 Day Moving Average – What’s Next?
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month High – What’s Next?
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of “Moderate Buy” from Analysts
Celldex to Present at Upcoming Investor Conference
SG Americas Securities LLC Has $1.29 Million Holdings in Celldex Therapeutics, Inc. $CLDX
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Biggest stock movers Thursday: RC, CLDX, and more
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
Celldex Therapeutics announces public offering of common stock
Celldex Announces Proposed Public Offering of Common Stock
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200 Day Moving Average – Should You Sell?
Celldex Therapeutics (NASDAQ:CLDX) Hits New 52-Week High on Analyst Upgrade
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Celldex Therapeutics (NASDAQ:CLDX) Trading 3.7% Higher – Should You Buy?
Celldex Therapeutics, Inc. $CLDX Shares Purchased by American Century Companies Inc.
Q3 Earnings Forecast for CLDX Issued By HC Wainwright
Celldex GAAP EPS of -$1.22 misses by $0.20, revenue of $0.12M misses by $1.34M
Celldex surges after completing enrollments in late-stage trials for lead asset
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile
Celldex to Present at Upcoming Investor Conferences
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Update
Celldex Therapeutics SVPs Engage In Heavy Transactions
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of “Moderate Buy” by Analysts
Celldex Therapeutics (NASDAQ:CLDX) Trading Up 4.1% – What’s Next?
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened
Corient Private Wealth LLC Purchases Shares of 201,717 Celldex Therapeutics, Inc. $CLDX
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
Fisher Asset Management LLC Sells 49,420 Shares of Celldex Therapeutics, Inc. $CLDX
American Century Companies Inc. Grows Position in Celldex Therapeutics, Inc. $CLDX